mk-7655 and Renal-Insufficiency

mk-7655 has been researched along with Renal-Insufficiency* in 1 studies

Trials

1 trial(s) available for mk-7655 and Renal-Insufficiency

Article	Year
Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin. British journal of clinical pharmacology, 2020, Volume: 86, Issue:5 Two phase 1, open-label studies were conducted to investigate the effect of renal impairment (RI) and organic anion transporter (OAT) inhibition on pharmacokinetics (PK) and safety of relebactam (REL) plus imipenem/cilastatin (IMI).. Study PN005 evaluated the PK of REL (125 mg) plus IMI (250 mg) in participants with RI vs healthy controls. Study PN019 evaluated the PK of REL (250 mg) and imipenem (500 mg; dosed as IMI) with/without probenecid (1 g; OAT inhibitor) in healthy adults.. RI increased plasma exposure and similarly decreased clearance of REL, imipenem and cilastatin; IMI/REL dose adjustment (fixed-ratio) will be required for patients with RI. Probenecid had no clinically meaningful impact on the PK of REL or imipenem. Topics: Adult; Aged; Azabicyclo Compounds; beta-Lactamase Inhibitors; Cilastatin; Drug Combinations; Female; Humans; Imipenem; Male; Middle Aged; Organic Anion Transporters; Renal Insufficiency; Young Adult	2020

Article

Year

Impact of renal impairment and human organic anion transporter inhibition on pharmacokinetics, safety and tolerability of relebactam combined with imipenem and cilastatin.

British journal of clinical pharmacology, 2020, Volume: 86, Issue:5

Two phase 1, open-label studies were conducted to investigate the effect of renal impairment (RI) and organic anion transporter (OAT) inhibition on pharmacokinetics (PK) and safety of relebactam (REL) plus imipenem/cilastatin (IMI).. Study PN005 evaluated the PK of REL (125 mg) plus IMI (250 mg) in participants with RI vs healthy controls. Study PN019 evaluated the PK of REL (250 mg) and imipenem (500 mg; dosed as IMI) with/without probenecid (1 g; OAT inhibitor) in healthy adults.. RI increased plasma exposure and similarly decreased clearance of REL, imipenem and cilastatin; IMI/REL dose adjustment (fixed-ratio) will be required for patients with RI. Probenecid had no clinically meaningful impact on the PK of REL or imipenem.

Topics: Adult; Aged; Azabicyclo Compounds; beta-Lactamase Inhibitors; Cilastatin; Drug Combinations; Female; Humans; Imipenem; Male; Middle Aged; Organic Anion Transporters; Renal Insufficiency; Young Adult

2020